Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Choline analogues in malaria chemotherapy.

Peyrottes S, Caldarelli S, Wein S, Périgaud C, Pellet A, Vial H.

Curr Pharm Des. 2012;18(24):3454-66. Review.

2.

Novel drug targets in malaria parasite with potential to yield antimalarial drugs with long useful therapeutic lives.

Muregi FW, Wamakima HN, Kimani FT.

Curr Pharm Des. 2012;18(24):3505-21. Review.

PMID:
22607143
3.

Parasitological and clinical efficacy of standard treatment regimens against Plasmodium falciparum, P. vivax and P. malariae in Papua New Guinea.

Genton B, Baea K, Lorry K, Ginny M, Wines B, Alpers MP.

P N G Med J. 2005 Sep-Dec;48(3-4):141-50.

PMID:
17212060
4.

The apicoplast: a key target to cure malaria.

MacRae JI, Maréchal E, Biot C, Botté CY.

Curr Pharm Des. 2012;18(24):3490-504. Review.

PMID:
22607142
5.

Towards histone deacetylase inhibitors as new antimalarial drugs.

Andrews KT, Tran TN, Fairlie DP.

Curr Pharm Des. 2012;18(24):3467-79. Review.

PMID:
22607140
6.

Current status of malaria control.

Tripathi RP, Mishra RC, Dwivedi N, Tewari N, Verma SS.

Curr Med Chem. 2005;12(22):2643-59. Review.

PMID:
16248819
7.

Transport and pharmacodynamics of albitiazolium, an antimalarial drug candidate.

Wein S, Maynadier M, Bordat Y, Perez J, Maheshwari S, Bette-Bobillo P, Tran Van Ba C, Penarete-Vargas D, Fraisse L, Cerdan R, Vial H.

Br J Pharmacol. 2012 Aug;166(8):2263-76. doi: 10.1111/j.1476-5381.2012.01966.x.

8.

Chemotherapy of malaria.

Talukdar B.

Indian Pediatr. 1986 May;23(5):371-5. No abstract available.

PMID:
3527970
9.

[Treatment of malaria in the 19th and 20th centuries].

Molfese A.

Clin Ter. 1999 Jan-Feb;150(1):81-5. Italian. No abstract available.

PMID:
10367548
10.

Inhibition of protein-protein interactions in Plasmodium falciparum: future drug targets.

Pierrot C, Fréville A, Olivier C, Souplet V, Khalife J.

Curr Pharm Des. 2012;18(24):3522-30. Review.

PMID:
22607144
11.

Why do Plasmodium malariae infections sometimes occur in spite of previous antimalarial medication?

Franken G, Müller-Stöver I, Holtfreter MC, Walter S, Mehlhorn H, Labisch A, Häussinger D, Richter J.

Parasitol Res. 2012 Aug;111(2):943-6. doi: 10.1007/s00436-012-2851-8. Epub 2012 Feb 18.

PMID:
22350675
12.

Will a global subsidy of new antimalarials delay the emergence of resistance and save lives?

Laxminarayan R, Over M, Smith DL.

Health Aff (Millwood). 2006 Mar-Apr;25(2):325-36.

14.

[Urgent problems of the treatment and pharmacologic prevention of malaria].

Kotłowski A.

Wiad Parazytol. 1988;34(4-6):503-7. Polish. No abstract available.

PMID:
3071914
15.

Novel rational drug design strategies with potential to revolutionize malaria chemotherapy.

Muregi FW, Kirira PG, Ishih A.

Curr Med Chem. 2011;18(1):113-43. Review.

PMID:
21110811
16.

Basic biochemical investigations as rationale for the design of original antimalarial drugs. An example of phospholipid metabolism.

Vial HJ, Angelin ML, Elabbadi N, Calas M, Cordinas G, Giral L.

Mem Inst Oswaldo Cruz. 1992;87 Suppl 3:251-61. Review.

17.

Lipoic acid metabolism of Plasmodium--a suitable drug target.

Storm J, Müller S.

Curr Pharm Des. 2012;18(24):3480-9. Review.

18.

Chemotherapy and drug resistance in malaria.

Cowman AF, Foote SJ.

Int J Parasitol. 1990 Jul;20(4):503-13. Review.

PMID:
2210944
19.

Perspective in antimalarial chemotherapy.

Kumar A, Katiyar SB, Agarwal A, Chauhan PM.

Curr Med Chem. 2003 Jul;10(13):1137-50. Review.

PMID:
12678807
20.

The next opportunity in anti-malaria drug discovery: the liver stage.

Derbyshire ER, Mota MM, Clardy J.

PLoS Pathog. 2011 Sep;7(9):e1002178. doi: 10.1371/journal.ppat.1002178. Epub 2011 Sep 22. No abstract available.

Items per page

Supplemental Content

Write to the Help Desk